Advanced drug delivery systems specialist SHL Medical said on Tuesday that it has entered a non-exclusive co-marketing partnership with contract development and manufacturing organisation (CDMO) Lifecore Biomedical (Nasdaq:LFCR).

Under this agreement, Lifecore joins SHL's Alliance Management programme, fostering customer engagement and knowledge exchange within the drug delivery ecosystem. SHL and Lifecore will exchange knowledge and experience in their respective fields, enabling both companies to enhance CDMO services and drug delivery device development.

SHL, known for autoinjectors, offers vertically integrated capabilities for device development, manufacturing, and final assembly. This partnership with Lifecore ensures access to a trusted CDMO with expertise in aseptic pharmaceutical manufacturing and container filling, offering comprehensive support throughout the autoinjector development and commercial lifecycle.